Details of the Drug | DrugMAP

General Information of Drug (ID: DM0GBB5)

Drug Name

PF-04634817

Indication

Disease Entry	ICD 11	Status	REF
Diabetic nephropathy	GB61.Z	Phase 2	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C25H36F3N5O3
Canonical SMILES: CC(C)C1(CCC(C1)NC2CCOCC2OC)C(=O)N3CC4CC3CN4C5=NC=NC(=C5)C(F)(F)F
InChI: 1S/C25H36F3N5O3/c1-15(2)24(6-4-16(10-24)31-19-5-7-36-13-20(19)35-3)23(34)33-12-17-8-18(33)11-32(17)22-9-21(25(26,27)28)29-14-30-22/h9,14-20,31H,4-8,10-13H2,1-3H3/t16-,17+,18+,19+,20-,24+/m1/s1
InChIKey: MCRWZBYTLVCCJJ-DKALBXGISA-N

Cross-matching ID

PubChem CID: 46198579
CAS Number: 1228111-63-4
UNII: 51M3FB9B9E
DrugBank ID: DB14955
TTD ID: D0D9HA

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

References

1	ClinicalTrials.gov (NCT01712061) A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy. U.S. National Institutes of Health.